Phaseline

Targets › BTLA

BTLA (B- and T-lymphocyte attenuator): drug programs, companies and trials

2 programs from 2 companies in 2 trials: 1 Phase 3, 1 Phase 2; Oncology; next expected readout Jan 2027.

Inhibitory receptor on lymphocytes that negatively regulates antigen receptor signaling via PTPN6/SHP-1 and PTPN11/SHP-2. May interact in cis (on the same cell) or in trans (on other cells) with TNFRSF14. (UniProt, Q7Z6A9)

Open in Phaseline: the race on BTLA, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Shanghai Junshi Bioscience Co., Ltd.Tifcemalimab
BTLA inhibitor (monoclonal antibody)
BTLAPhase 3Limited-stage Small Cell Lung Cancer (LS-SCLC)Jul 2027
Shanghai Pulmonary Hospital, Shanghai, ChinaJS004 (tifcemalimab)
BTLA inhibitor antibody
BTLAPhase 2Limited Stage Small Cell Lung CancerJan 2027

Conditions

Limited-stage Small Cell Lung Cancer (LS-SCLC) (1) Limited Stage Small Cell Lung Cancer (1)

Modalities

antibody (1), mixed (1)

Companies

Shanghai Junshi Bioscience Co., Ltd. (1) Shanghai Pulmonary Hospital, Shanghai, China (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.